Skip to main content

TTX-030 in Combination With Immunotherapy and / or Chemotherapy in Subjects With Advanced Cancers

Trial Status: Active

This is a phase 1 / 1b study of TTX-030 in combination therapy, an antibody that inhibits CD39 enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of immunosuppressive adenosine, which may change the tumor microenvironment and promote anti-tumor immune response. This trial will study the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TTX-030 in combination with immunotherapy and / or standard chemotherapies.

Inclusion Criteria

  • Age 18 years or older, is willing and able to provide informed consent
  • Histologically confirmed diagnosis of unresectable or metastatic solid tumor malignancy in selected tumor types
  • Life expectancy > 12 weeks
  • ECOG performance status of 0-1

Exclusion Criteria

  • History of allergy or hypersensitivity to study treatment components. Patients with a history of severe hypersensitivity reaction to any monoclonal antibody.
  • Use of investigational agent within 28 days prior to the first dose of study treatment and throughout the study
  • Receiving high-dose systemic steroid therapy or any other form of immunosuppressive therapy
  • History of severe autoimmune disease
  • Uncontrolled intercurrent illness or other active malignancy requiring ongoing treatment

California

Los Angeles
UCLA / Jonsson Comprehensive Cancer Center
Status: IN_REVIEW
Contact: Lisa Yonemoto
Phone: 310-825-4477

Ohio

Cleveland
Case Comprehensive Cancer Center
Status: IN_REVIEW

Trial Phase Phase I

Trial Type Treatment

Lead Organization
Tizona Therapeutics, Inc

  • Primary ID TTX-030-002
  • Secondary IDs NCI-2020-02350
  • Clinicaltrials.gov ID NCT04306900